Global Xenotransplantation Market – Industry Trends and Forecast to 2029

Market Analysis and Size

Transplantation is a successful therapy option for end-stage organ failure. The disparity between supply and demand for human organs, on the other hand, is a bottleneck for clinical transplantation. As of January 2019, more than 113,000 people were on the transplant waiting list in the United States, according to the US Government Information on Organ Donation and Transplantation, whereas only 36,528 transplants were done in 2018.

Data Bridge Market Research analyses that the xenotransplantation market which was USD 12.95 billion in 2021, would rocket up to USD 24.51 billion by 2029, and is expected to undergo a CAGR of 8.30% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Any procedure that involves the transplantation, implantation, or infusion into a human recipient of either live nonhuman animal cells, tissues, or organs, or human body fluids, cells, tissues, or organs that have had ex vivo contact with live nonhuman animal cells, tissues, or organs, is referred to as xenotransplantation. The demand for human organs for clinical transplantation significantly outnumbers the availability, which has fueled the development of xenotransplantation.

Xenotransplantation Market Dynamics

Drivers

• Rise in surgeries

In the forecast period of 2022-2029, the rising volume of organ transplantation surgeries, rising occurrences of chronic diseases, rising investment for the development of advanced and technical products, and the growing number of geriatric population are some of the factors that will likely boost the growth of the xenotransplantation market. Changing lifestyles among the rising population, on the other hand, would enhance numerous opportunities, resulting in the rise of the xenotransplantation market throughout the forecast period.

• Increasing demand for tissue and organ transplantation

Organ failure can be caused by a variety of things, including minor trauma, blood loss, poisoning, and drug usage. The rising prevalence of kidney disease, excessive alcohol intake, and a poor diet have all contributed to the expansion of the Organ Transplantation industry. Chronic sickness and organ failure affect a large portion of the population.

• Improved understanding of immune system

One of the success stories of the second half of the twentieth century is organ transplantation. Indeed, it is its success, which has resulted in the referral of ever-increasing numbers of patients, that has caused a shortage of donor organs. Our improved understanding of the immune system and the immune rejection process has led to the development of therapies that, hopefully, will overcome the robust immune responses associated with xenogeneic tissue transplantation. Human clinical trials utilising animal cells and organs to treat some of these diseases are expected to become a reality in the coming years.

Opportunities

• Xenotransplantation could still be beneficial without long-term success

Even though xenotransplantation research has so far yielded mixed results in terms of extending life, allowing people who are waiting for organs to utilise animal organs could help them survive longer until they can obtain human organs. It will keep the black market at bay. Although it is dangerous to sell human organs on the illicit market, some people consider it as a last resort when they are desperate to preserve their lives. The use of animal organs as a substitute could help to minimise this exploitative trade, which is extremely dangerous because the quality and condition of the organs, as well as how they were obtained, are unknown.

Restraints/Challenges

Treatment of failure is helping to develop the market, as is technological innovation and an increase in the number of issuing banks. Globally, there is a surge in demand for organ replacement, particularly kidney, heart, and liver transplants. The market is hampered by the high cost of transplantation, which includes the high cost of completed services, the restricted number of donors accessible, and the number of failures that occur. Patients are becoming more concerned as the prevalence of organ failure rises. The shortage of resources available on the market is one of the issues.

This xenotransplantation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the xenotransplantation market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Covid-19 Impact on Xenotransplantation Market

Many people who would benefit from organ transplantation are unable to do so because human organ donation is insufficient to meet medical demands. Xenotransplantation has the potential to provide infinite access to pig organs for transplantation, and pig-to-non-human primate models have shown promising results that could soon lead to clinical trials. However, one of the specific ethical issues of xenotransplantation is that the risk of spreading zoonotic disease into the community must be evaluated against the patient's benefit. While most specialists feel that zoonosis can be controlled, many people who are hesitant or opposed to clinical xenotransplantation are concerned about disease transfer from animal donors to human recipients. The COVID-19 pandemic represents a scenario (fast global spread of a highly contagious novel zoonotic disease with no natural human defence) that would appear to warrant concern, particularly in the United States, which has mostly evaded prior pandemic outbreaks. However, there are numerous variations between zoonosis found in the wild and zoonosis acquired during xenotransplantation that favour the latter's safety. Outside of the field, however, these distinctions, as well as the advantages of xenotransplantation, are not well appreciated. As a result, we must consider the impact of the COVID-19 epidemic on attitudes regarding xenotransplantation.

Global Xenotransplantation Market Scope

The xenotransplantation market is segmented on the basis of product type and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Organ Preservation Solutions
•  Transplant Diagnostics
• Tissue Products
   

Applications

• Heart
•  Kidney
•  Other Organs

Xenotransplantation Market Regional Analysis/Insights

The xenotransplantation market is analysed and market size insights and trends are provided by country, product type and application as referenced above.

The countries covered in the xenotransplantation market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominating the xenotransplantation market due to the growing development in the medical sector along with increasing cases of organ failure.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the growing pool of population along with prevalence of various market manufacturers.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Xenotransplantation Market Share Analysis

The xenotransplantation market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to xenotransplantation market.

Some of the major players operating in the xenotransplantation market are:

• Terumo Medical Corporation (Japan)
• Transonic (U.S)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Astellas Pharma, Inc. (Japan)
• Preservation Solutions, Inc. (U.S)
• OrganOX Limited (U.K)
• Bio Med Pvt. Ltd. (U.S)
• Transplant Biomedical (Spain )
• TransMedic, Pte. Ltd. (Singapore)
• Novartis AG (Switzerland)
• Organ Recovery Systems (U.S)
• Accord Healthcare (U.S)
• Pfizer, Inc (U.S)
• Veloxis Pharmaceuticals, Inc. (U.S)

SKU-53139